14,396 Shares in Soleno Therapeutics, Inc. (NASDAQ:SLNO) Acquired by Virtu Financial LLC

Virtu Financial LLC acquired a new position in Soleno Therapeutics, Inc. (NASDAQ:SLNO) in the 1st quarter, Holdings Channel reports. The institutional investor acquired 14,396 shares of the company’s stock, valued at approximately $1,029,000.

Other institutional investors have also recently bought and sold shares of the company. Summit Investment Advisors Inc. raised its position in shares of Soleno Therapeutics by 24.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 2,677 shares of the company’s stock valued at $120,000 after acquiring an additional 522 shares during the last quarter. Avanza Fonder AB boosted its stake in Soleno Therapeutics by 14.8% in the 1st quarter. Avanza Fonder AB now owns 1,951 shares of the company’s stock worth $144,000 after purchasing an additional 251 shares during the period. Tower Research Capital LLC TRC boosted its stake in Soleno Therapeutics by 811.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,304 shares of the company’s stock worth $193,000 after purchasing an additional 3,832 shares during the period. Oppenheimer & Co. Inc. bought a new stake in Soleno Therapeutics during the 1st quarter worth about $232,000. Finally, GAMMA Investing LLC lifted its position in Soleno Therapeutics by 4,377.3% during the 1st quarter. GAMMA Investing LLC now owns 3,358 shares of the company’s stock worth $240,000 after buying an additional 3,283 shares in the last quarter. Institutional investors own 97.42% of the company’s stock.

Soleno Therapeutics Price Performance

Shares of Soleno Therapeutics stock opened at $85.76 on Tuesday. The company has a fifty day moving average of $82.86 and a 200-day moving average of $68.62. Soleno Therapeutics, Inc. has a 52-week low of $41.50 and a 52-week high of $90.32. The company has a debt-to-equity ratio of 0.21, a quick ratio of 15.01 and a current ratio of 15.13. The stock has a market capitalization of $4.56 billion, a price-to-earnings ratio of -20.71 and a beta of -2.56.

Soleno Therapeutics (NASDAQ:SLNO) last posted its earnings results on Wednesday, August 6th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.44. The company had revenue of $32.66 million during the quarter, compared to analysts’ expectations of $3.91 million. Equities research analysts expect that Soleno Therapeutics, Inc. will post -3.72 EPS for the current year.

Insider Activity at Soleno Therapeutics

In related news, insider Patricia C. Hirano sold 3,830 shares of the firm’s stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $82.76, for a total value of $316,970.80. Following the transaction, the insider owned 13,206 shares of the company’s stock, valued at approximately $1,092,928.56. This trade represents a 22.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 6.40% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on SLNO shares. Guggenheim upped their target price on shares of Soleno Therapeutics from $97.00 to $106.00 and gave the company a “buy” rating in a report on Thursday, August 7th. Robert W. Baird set a $121.00 target price on shares of Soleno Therapeutics and gave the stock an “outperform” rating in a research report on Friday, July 11th. Wall Street Zen upgraded shares of Soleno Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, July 26th. Cowen reiterated a “buy” rating on shares of Soleno Therapeutics in a research report on Thursday. Finally, HC Wainwright reissued a “buy” rating and issued a $100.00 price objective on shares of Soleno Therapeutics in a research note on Tuesday, April 15th. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $113.30.

Soleno Therapeutics Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.